$600,000 Award From NIIMBL!
We are very excited to announce the reception of a $600,000 award from NIIMBL for the development of next generation CCTC.
The 1-year project to commercialize our next generation platform involves a cooperative project agreement with the computation fluid dynamics team from Penn State under the leadership of Dr. Ali Borhan. The project is also supported by Genentech and Merck which will provide testing material, scale up support, and analytical expertise.
This work is performed under a Project Award Agreement from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) and financial assistance award 70NANB17H002 from the U.S. Department of Commerce, National Institute of Standards and Technology.
Over 50% Of The $3M Series A Equity Round Raised!
We are very happy to announce that ChromaTan has now raised over 50% of the $3 Million Series A equity round.
$1.57 Million has now been raised from several angel investor groups and individuals that include Lehigh Valley Angels, Social Venture Circle, Mid-Atlantic Diamond Ventures, and Sorensen Family office.
For more information on the round please contact Oleg Shinkazh, CEO at firstname.lastname@example.org.
CEO Oleg Shinkazh Interviewed By Biostrategy Forum
CEO Oleg Shinkazh was interviewed by Biostrategy Forum. The conversation centered around strategic partnerships, investor relations, and customer acquisition.
New Paper Published In Partnership With Merck!
We are thrilled to announce a publication of a landmark paper in partnership with Merck titled “Improved protein A resin for antibody capture in a continuous countercurrent tangential chromatography system”.
The paper features the highest ever recorded productivity in a resin-based Protein A capture process of 140 grams of mAb/ Liter of resin / hr. We would also like to thank our partners from Purolite Life Sciences for working with on innovating a new type of small particle agarose resin that enabled such high process efficiencies.
New Patent Published!
We would like to announce a publication of our new patent titled “High efficiency continuous countercurrent tangential chromatography”.
The patent features a significant improvement of the flow path design for the CCTC platform and extends our exclusivity by 5 years to 2034!
Partnership With MIT And Takeda!
We are very happy to announce a partnership with MIT and Takeda on a 2-year $750,000 contract awarded by the Massachusetts Life Sciences Center.
The award will sponsor a sale of our first commercial CCTC pilot system as well as support an extensive evaluation of the platform by Takeda. The work will be performed at the newly created continuous bioprocessing center at MIT under the leadership of Dr. Richard Braatz. The group at MIT will be working with the Chromatan team on creating a detailed dynamic modeling tool designed for extensive characterization of the CCTC platform for integrated continuous bioprocessing.
ChromaTan Graduates From Incubation!
We have now moved into a newly renovated facility in Springhouse Innovation Park! The facility for completely renovated for our needs and will serve as our new corporate headquarters and demonstration facility for the CCTC platform!
This wonderful innovation park is located about 35 min North-West of Philadelphia and is also the home of the Jefferson Institute of Bioprocessing (JIB) which opened its doors in September 2019.
Please note our new address:
3 Springhouse Innovation Park Suite 103
Lower Gwynedd, PA, 19002
ChromaTan Is Sponsoring The CCP Summit In Boston
On Continuous Bioprocessing!
Read the interview with CEO Oleg Shinkazh about the advantage and challenges of Continuous Bioprocessing for Biologics, click here to download the PDF.
The event is being held at the Hyatt Regency Hotel January 29th – 31st.
Please come visit our booth and talk at 12:30 pm ET on January 30th.
Click here for full event details.
ChromaTan Wins An Investor Pitch Competition
At The Comcast Center In Philadelphia!
Our reward is a guaranteed entrance to PACT 2019, one of the most prestigious venture conferences PACT in 2019!
Winner’s badge below:
Norman Sorensen And Son Erik Sorensen Invest $200,000 In A Convertible Bridge Into ChromaTan And Pledge $150,000 More Towards Series A
Norman Sorensen is Former Chairman, President & CEO of Principal International, the global business holding company of Principal Financial Group (Nasdaq: PFG), where from 1998 through 2012 he was responsible for managing over $120 Billion in pension, retirement, annuities, mutual funds and asset management businesses with over 10 million customers in 12 countries.
A Quote from Norman on the attractiveness of ChromaTan as an investment opportunity is below:
“My base notion about investing in ChromaTan has been the understanding that the population of the US and other developed nations around the world is rapidly aging because of the baby boomers generation. This is happening at such a rate that it's no longer acceptable for governments to be in the position to continue to defray entitlement costs of Medicare and Medicaid going forward. Some measures have to be taken before these programs inevitably go bankrupt. There are only two ways to solve this - to decrease costs through innovation and/or cutting entitlements.
Development and drug manufacturing are major costs, and methods of production are antiquated. ChromaTan's innovation is a very compelling message by elegantly addressing a major challenge for biologics production. I think the company could become an important contributor to helping solve the crisis of healthcare costs which in my opinion is a major “civilization challenge” that must be tackled.”
Interested Investors - please inquire with CEO Oleg Shinkazh at email@example.com
ChromaTan and PendoTECH Co-Publish A White Paper On The Utilization Of In-Line Sensors In Continuous Processing In Bioprocess International
To read the white paper, click here [PDF].
ChromaTan Signs A $100,000 R&D Contract With Largest Biopharma In The World – Roche
Roche and ChromaTan have signed a $100,000 R&D contract. The purpose of the work is to demonstrate the capabilities of the CCTC platform as applied to a commercial antibody-based therapy in Roche’s pipeline. An extensive letter of support has been executed by Wolfgang Koehnlein, who is the lead of the project from Roche. Please contact ChromaTan to request the letter.
NIH Supplements ChromaTan With $255,000 Award!
ChromaTan receives an additional award for $255,000 from the NIH to supplement its current Phase II $1.5M NIH SBIR grant! The award will fund the supplemental equipment necessary to accomplish the integration of CCTC with the perfusion bioreactor into a single continuous unit operation!
Applikon Biotechnology And ChromaTan Co-Publish A White Paper On The Development On The Integrated Continuous And Single-Use Bioproduction Platform (ICS)
The paper explores the optimization of Perfusion and Cell separation device (Biosep) and outlines data collected during the Phase I portion of the NIH grant award.
To read click here [PDF].
GEN Magazine Features Two Articles That Discuss The ChromaTan Platform!
Recent edition of Genetic Engineering & Biotechnology News (GEN) journal features both articles in a special edition entitled, “Continuous Bioprocessing: Brave Old Challenges with Bold New Technologies”. ChromaTan’s (CCTC) platform was highlighted in the articles below:
“Visions of a Continuous Bioprocess Future” by Josh Roberts
“Continuous Processing’s Benefits within Biopharma’s Reach” by Applikon’s Erik Kakes
Bioprocessing Summit Booth & Presentation
At the Bioprocessing Summit 2018, ChromaTan shared an exhibitor’s booth with Purolite, one of the world’s largest manufacturers of chromatography media in the world.
Dmitriy Fedorenko – our Associate Director of Process Sciences presented a technical talk entitled, “Paving the Way to integrated Continuous Bioprocessing: In-line PAT for Steady-State Purification with the CCTC Platform”.
ChromaTan Presents At The BIO Conference
ChromaTan hosted an exhibition booth in the “Emerging Innovators Zone” at the BIO 2018 conference held in Boston with CEO Oleg Shinkazh presenting a 10-min pitch on the company and its platform.
ChromaTan Receives The Numera System With Lucullus Software Licenses From Partner Securecell
ChromaTan and Securecell are partnering to introduce Securecell’s state-of-the-art Lucullus software solution and the Numera in-line sampling platform to be integrated into the ChromaTan’s continuous bioprocessing solutions for process control and in-line sample prep and analysis. The software solution will power the CCTC system and provide a single interface across all involved devices. The Numera system will provide in-line sampling for the multiple unit operations and closes the links between the bioprocesses and the necessary reference analytics. The combination of both enables advanced monitoring and process control along the whole process chain.
BPI Europe – ChromaTan CEO Oleg Shinkazh Presents The ChromaTan Platform To European Audiences
The joint presentation with partners Purolite drew a substantial crowd!
ChromaTan And University of Maryland Are Awarded $600,000 From NIIMBL
The award will be used to develop in-line NMR instrument for measurements of protein concentration and aggregation. This is the very first award in the history of NIIMBL. For more details on the award click for press release here.
ChromaTan Receives A $2.5 Million Contract From The FDA
for the development of a new continuous purification platform for single-use and continuous bio-manufacturing.
Please click the links below for various versions of the news:
September 25th–28th 2017 – Bioprocess International (BPI) Showcase In Boston, MA
COME AND VISIT US
AT BOOTH 1323!
Oleg Shinkazh, CEO of ChromaTan will be giving a featured talk at 2:30 p.m. on Wed September 27th on development and implementation of end-to-end continuous bioprocessing. He will be joined by Purolite's Application Manager Hans Johannson.
On the conference floor we will be featuring the beta version of our Process Development CCTC system.
CCTC Processs Development System
Our partner Purolite Life Sciences will be joining us at BPI to showcase our new resin, jetting, and bioprocess technologies. Please read about our partnership at this link (PDF).
ChromaTan opens a new location in Philadelphia Science Center!
Our address in Philadelphia is:
3624 Market Street Suite 5E
Philadelphia, PA 19104
The company will be performing all laboratory and business functions out of this new location while the engineering department completes design and construction of the Process Development CCTC system in State College, PA.
ChromaTan, Eli Lilly, and Penn State publish a seminal paper in Journal of Chromatography A after a long-term R&D collaboration!
The work showcases fantastic results of applying the CCTC platform to mixed-mode polishing chromatography.
ChromaTan and Purolite Corporation execute a strategic collaboration on chromatography resin development that resulted in an innovative new resin product that was specifically designed for the
CCTC platform. Click the link below to read the announcement!
PUROLITE LIFE SCIENCES AND CHROMATAN COLLABORATE TO INCREASE PROTEIN A RESIN PRODUCTIVITY BY UP TO 15X
ChromaTan receives a $500,000 infusion of capital from Life Science Greenhouse of Central PA and invites their portfolio manager Steve Carpenter to the company board!
ChromaTan receives a $100,000 infusion of capital from Blue Tree Venture Partners.
ChromaTan grows the company headcount to 7 empoyees by hiring Bill Muzika as a Controls Engineer and Jonathan Walko as an Associate Engineer.
ChromaTan completes the Phase I milestones for the Fast Track Phase II SBIR, gaining access to $1.5 Million in funds over the next two years to complete the Integrated Continuous and Single-Use bioproduction platform.
ChromaTan publishes a peer reviewed publication in Biotechnology Progress.
The paper is focused on detailed discussion of performance optimization of the CCTC platform for antibody capture.
ChromaTan received a $1.73 Million Fast-Track Phase II SBIR grant award for the development of ICS – Integrated Continuous and Single-use bio-production platform. The development
efforts over the next 3 years will focus on integrating CTC technology with perfusion bioreactors resulting in the first of its kind single-use platform for producing and purifying biologics in a
ChromaTan received technology endorsement from three of our future customers MedImmune / Astrazeneca, Regeneron, and NRC Canada. The
letters describe our testing efforts and lay out intentions for further commercialization and sales of CCTC technology. One of the letters is attached, click here to view!
ChromaTan welcomes Dr. Soroosh Soltani and Dmitriy Fedorenko to our team, taking our head count to 6! These additions will significantly strengthen ChromaTan’s technical group with talent and expertise in both upstream and downstream processing!
ChromaTan raises additional $170,000 of convertible debt from new investors!
ChromaTan is featured in GEN magazine company profile!
Read article here: ChromaTan Purifies against the Current
ChromaTan files a PCT patent for new claims on CTC system improvements, additional operational modes and methods!
ChromaTan publishes a landmark peer reviewed paper in the special addition of the Journal of Biotechnology on Continuous processing. This
publication was more than 1 year in the making, and involved collaborations and co-authorships from Penn State University, Fujifilm Diosynth, and Regeneron!
Read publication here: Purification of monoclonal antibodies from clarified cell culture fluid using Protein A capture continuous countercurrent tangential chromatography
ChromaTan is featured in GEN magazine’s Bioprocessing Perspective! Click here to read the article.
ChromaTan submits a major publication to Journal of Biotechnology. The paper is co-written with Penn State, Fujifilm Diosynth and Regeneron
ChromaTan completes the CTC demo system and starts the ChromaTan blitz - a technology demonstration campaign with our first early adoption candidate.
ChromaTan receives additional funding from NIH on the Phase II extension for $175,000!
- ChromaTan presented data that was jointly generated with Fujifilm Diosynth and Regeneron Pharmaceuticals at several industry conferences including Prep, Recovery, ManuBio and Bioprocess International. The results showed 4-5 times productivity increase over the status quo technology with comparable purity and yield. The data causes significant excitement in the industry and leads to several technology evaluation requests from major antibody manufacturers.
ChromaTan was awarded Phase II funding from the National Institute of Helath (NIH) for $985,000! This is a major milestone for our team and
serves as a major validation for all the hard work that our team has been doing!
Some excerpts from the summary review statements:
"... This Phase II project has high significance because it describes a way to more cheaply purify proteins on
large scale as needed for biopharmaceutical production. The innovation is high because the basic concept of the chromatography is new and appears to offer significant advantages"
".... This is an exciting prospect for those that depend on the production of such compounds. This is highly significant"
"... The CCTC system is a novel approach to using selective resins, like Protein A, in the purification of large amounts of protein. The resin is efficiently used unlike a conventional column where much of the column is “waiting” for the sample. This is clever engineering."
ChromaTan was recently awarded an investment of $225,000 from Ben Franklin Technology Partners of Central PA! The funds will be used to boost the development of CCTC and increase ChromaTan's headcount to five!
ChromaTan and ASI have been featured on Pharmaceutical Technology in the article entitled "Single-Use Continuous Chromatography Overcoming Limitations of Traditional Protein Purification" by Dr. Cynthia Challener. Below is a short blurb:
Continuous countercurrent tangential chromatography combines the principles of chromatography and
continuous/conveyor-belt processing with liquid–liquid extraction and tangential flow filtration to create the first “true moving bed” technology (as opposed to simulated moving bed) that is capable
of large-scale, column-free capture purification of biologics, according to Shinkazh.
Initially developed by Chromatan and now under joint development by Chromatan and ASI, the Evopure system preserves the robust resin interaction and buffer chemistry of column chromatography while using a flow path specifically designed for single-use operation.
The Evopure system addresses three critical needs of the purification industry—cost savings on capital and operational costs, a single-use and sterile flow path, and linear scalability, according to Smeltz. Specifically, with CCTC, throughput is increased 5- to 10-fold when compared to conventional columns, which enables high resin cycling in a single batch. CCTC thus, makes single-use capture practical and introduces significant cost savings of up to 65% to the end user, according to Shinkazh.
Click Here To Read More
ChromaTan publishes "Continuous Countercurrent Tangential Chromatography for Monoclonal Antibody Purification", a landmark paper in Separation Science and Technology!
In-Pharma technologist highlights ChromaTan's partnership with ASI with exclusive podcast interview of ASI's president Kent Smeltz and ChromaTan's CEO Oleg Shinkazh! Click here to listen to the podcast (Internet Explorer is recommended).
ChromaTan closes the seed round at $560,815 by raising $227,815 from angel investors, friends and family!
ChromaTan featured in Centre Daily Times news article "Programs, Grants Help Boost Business"!
ChromaTan welcomes our new VP of engineering Boris Napadensky!
ChromaTan moves into new office and laboratory space in the wonderful technology incubator at 200 Innovation park in State College, PA
ChromaTan is funded by Ben Franklin Technology Partners of Central PA with a $150,000 debt investment!
ChromaTan signs a material transfer agreement with FujiFilm Diosynth.
ChromaTan hires Dr. Achyuta Teella to begin work on the continuous CTC prototype system! Welcome aboard!
ChromaTan received an Phase 1 SBIR Award from the National Institute of Health (NIH) for $183,000 to construct a pilot Countercurrent Tangential Chromatography system!
ChromaTan's Countercurrent Tangential Chromatography Methods, Systems, And Apparatus patent has been issued! You may download a PDF copy of the patent from the Intellectual Property section for review.
ChromaTan's Continuous Countercurrent Tangential Chromatography System patent has been issued! You may download a PDF copy of the patent from the Intellectual Property section for review.
ChromaTan's article titled 'Countercurrent tangential chromatography for large-scale protein purification' has been published in Volume 108, Issue 3 March 2011 of Biotechnology and Bioengineering.
ChromaTan advances to the finals of Masschallenge! Masschallenge is a competition for startup companies.
ChromaTan will be moving into the accelerator stage of the program for a chance to win $100,000 dollars! More details at http://www.masschallenge.com.
ChromaTan wins funding grant from Ben Franklin Technology Partners.
Spectrum is now an investor in ChromaTan.
Getting Real with Downstream Processing, GEN
"Like all areas of bioprocessing, downstream purification has its own favored buzzwords—titers, bottlenecks, capacity, and others—meant to evoke a particular response depending on who is speaking or writing them. But, if we could just identify one leading, universal trend in downstream bioprocessing, it would be simplification."
The ChromaTan team successfully created an innovative solution in countercurrent chromatography at the Penn State University Fenske Laboratory based on a patent pending design.
Feasibility studies completed - BSA/Myoglobin separation, excellent recovery, purity and hydrodynamic stability achieved.
Partnership with Penn State and Dr. Andrew Zydney established.
ChromaTan is officially incorporated.